Evidence map›Paper›PMID 35906490›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2022

In vivo brain endocannabinoid metabolism is related to hippocampus glutamate and structure - a multimodal imaging study with PET,

Jeremy J Watts, Elisa Guma, Sofia Chavez, Rachel F Tyndale, Ruth A Ross, Sylvain Houle, Alan A Wilson, Mallar Chakravarty, Pablo M Rusjan, Romina Mizrahi

Open access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Radiopharmaceuticals and their applications in medicine.Signal transduction and targeted therapy · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Jeremy J WattsResearch Centre, CHU Sainte-Justine, Montreal, QC, Canada.
Elisa GumaComputational Brain Anatomy (CoBrA) Laboratory, Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, QC, Canada.
Sofia ChavezBrain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Rachel F TyndaleDepartment of Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-1297-2053
Ruth A RossDepartment of Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada.
Sylvain HouleBrain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Alan A WilsonBrain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Mallar ChakravartyComputational Brain Anatomy (CoBrA) Laboratory, Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, QC, Canada.
Pablo M RusjanDepartment of Psychiatry, McGill University, Montreal, QC, Canada.ORCID http://orcid.org/0000-0003-0075-2918
Romina MizrahiDepartment of Psychiatry, McGill University, Montreal, QC, Canada. romina.mizrahi@mcgill.ca.ORCID http://orcid.org/0000-0001-6667-7928
Centre for Addiction and Mental Health · CADouglas Mental Health University Institute · CAUniversity of Toronto · CA

Funding

Imaging Alterations in Endocannabinoid Metabolism in Clinical High Risk and First Episode PsychosisR01MH113564 · NIMH · MCGILL UNIVERSITY · PI MIZRAHI, ROMINA · 2017 to 2022
$2.2M
Imaging Neuroinflammation in Clinical high risk and SchizophreniaR01MH100043 · NIMH · CENTRE FOR ADDICTION AND MENTAL HEALTH · PI MIZRAHI, ROMINA · 2014 to 2018
$1.6M
Imaging Alterations in Endocannabinoid Metabolism in SchizophreniaR21MH103717 · NIMH · CENTRE FOR ADDICTION AND MENTAL HEALTH · PI MIZRAHI, ROMINA · 2014 to 2015
$294k
CIHR FDN-154294NIMH NIH HHS R01 MH100043NIMH NIH HHS R01 MH113564NIMH NIH HHS R21 MH103717
6 · The paper itself

Abstract

Dysregulation of hippocampus glutamatergic neurotransmission and reductions in hippocampal volume have been associated with psychiatric disorders. The endocannabinoid system modulates glutamate neurotransmission and brain development, including hippocampal remodeling. In humans, elevated levels of anandamide and lower activity of its catabolic enzyme fatty acid amide hydrolase (FAAH) are associated with schizophrenia diagnosis and psychotic symptom severity, respectively (Neuropsychopharmacol, 29(11), 2108-2114; Biol. Psychiatry 88 (9), 727-735). Although preclinical studies provide strong evidence linking anandamide and FAAH to hippocampus neurotransmission and structure, these relationships remain poorly understood in humans. We recruited young adults with and without psychotic disorders and measured FAAH activity, hippocampal glutamate and glutamine (Glx), and hippocampal volume using [

Indexed as

EndocannabinoidsGlutamic AcidArachidonic AcidsBrainFemaleGlutamineHippocampusHumansMagnetic Resonance ImagingMaleMultimodal ImagingPolyunsaturated AlkamidesPositron-Emission TomographyProton Magnetic Resonance SpectroscopyYoung AdultanandamideArachidonic AcidsEndocannabinoidsGlutamic AcidGlutaminePolyunsaturated Alkamides

Identifiers

PMID35906490
PMCPMC9485131
OpenAlexW4288708392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.